Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	76.92B +10.4%
Revenue (ttm)	18.66B +6.0%
Net Income	4.73B +9.2%
EPS	18.04 +9.5%
Shares Out	262.98M
PE Ratio	16.21
Forward PE	11.09
Dividend	5.78 (1.98%)
Ex-Dividend Date	Aug 11, 2025

Volume	9,862,521
Average Volume	7,029,776
Open	311.50
Previous Close	324.50
Day's Range	292.50 - 312.00
52-Week Range	172.50 - 369.50
Beta	0.39
RSI	37.68
Earnings Date	Mar 5, 2026

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.